

Study Newsletter 12 May 2025



IMPORTANT INFORMATION: PASCAR & NIGERIAN CARDIAC SOCIETY CONFERENCE 2025, ABUJA, NIGERIA

MESSAGE FROM THE STUDY CHAIR

Dear Investigators,

The PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria, will take place 14 - 19 September 2025. Please indicate by clicking on the link in the MEETINGS 2025 section below whether you would be able to attend and participate in the THESUS-HF II Workshop Session on 16 September 2025, from 14:00 **onwards**, taking place at the conference.

Regards,

Karen Sliwa (THESUS-HF II Principal Investigator)



## PATIENT DATA COLLECTION CONFIRMATION

to indicate the number of days data collected: **CLICK HERE TO COMPLETE** 

Please complete the Patient Data Collection Confirmation form,



**MEETINGS 2025** 

Please click on the link to indicate your provisional attendance on the Meeting Survey Form.

<u> 14 - 19 September</u> Kindly take note: A THESUS-HF II Study Session Meeting will take

PASCAR & Nigerian Cardiac Society Conference 2025, Abuja, Nigeria

place during the PASCAR & 54th Annual General Meeting and Scientific Conference, providing an opportunity for you to present feedback and an abstract related to the THESUS-HF II Study. Date Time

16 September 2025

From 14:00 Onwards

(Nigerian Standard Time)



## Thank you to all those who completed the site information, sites who have not uploaded their site

SITE INFORMATION

information yet, please do so on REDCAP as soon as possible.



**ABSTRACTS SUBMITTED** 

Congratulations to everyone! Three THESUS-HF II Study abstracts have been submitted, with THREE accepted. Refer to the details provided below in the newsletter.

Our heartfelt thanks go out to all the participating sites for their tremendous effort and dedication in making this study a success thus far.

The THESUS-HF II Study abstracts were submitted to the following publications:

ACCEPTED for ESC HFA, Belgrade 17 - 20 May 2025: The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):

Access to Care ACCEPTED to ESC Congress, Madrid 29 Aug - 1 Sep: The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II):

ACCEPTED to ESC Congress, Madrid 29 Aug - 1 Sep: The Sub-Saharan Africa Survey of Heart Failure (THESUS-HF II): **In-hospital Outcomes** 

Access to Care



Usage and Dosing of Guideline-Directed Medical Therapies in African Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction

**UPTITRATION SUB-**STUDY REDCap PORTAL

Guidelines recommend starting and quickly increasing guideline-directed medical therapy (GDMT) within six weeks of heart failure (HF) hospitalization to reduce rehospitalization and mortality risk. However,

there is a gap between these recommendations and actual practices, leaving many patients with HFrEF and HFmrEF in Africa on suboptimal therapy. This Sub-study aims to: 1. Assess the proportion of HFrEF and HFmrEF patients initiating ACEI/ARB/ARNI, MRA, beta-blockers, and SGLT2i before hospital discharge. 2. Evaluate initiation of these medications within 30 days of discharge.

- 3. Evaluate initiation within 60 days of discharge. 4. Determine the proportion achieving target doses of ACEI/ARB/ARNI, MRA, and
- beta blockers at 180 days post-discharge compared to baseline. CLICK HERE to complete Sub-Study information on REDCap

PASCAR THESUS-HF II Study Steering Committee Principal Investigator: Karen Sliwa

Co-investigator: Albertino Damasceno, Charle Viljoen, Mahmoud Sani, Gad Cotter **Sub-investigator:** Neusa Jessen, Simon Stewart

Connect with PASCAR here





CAPE HEART INSTITUTE







ANNUAL

- Telemedicine and Digital Technology for Cardiovascular Care.
- •Role of Primary Care and Community Health Workers in Cardiovascular Disease Prevention and Management. • Taming the Scourge of Sudden Cardiac Death in Africa.

**10 CME POINTS AVAILABLE.** 



9

14 - 19 September 2025

Shehu Musa Yar'adua Centre, Abuja

**REGISTRATION & ABSTRACT PORTAL NOW OPEN** 

www.nigeriancardiacsociety.com